1. Academic Validation
  2. A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis

A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis

  • Nat Commun. 2026 Mar 11;17(1):3794. doi: 10.1038/s41467-026-70463-7.
Jianwen Song # 1 Xiaoying Kang # 1 Shuxuan Yang 1 Xue Meng 1 Zihang Shi 1 Wen Li 2 Ji Qi 3
Affiliations

Affiliations

  • 1 State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, and Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin, China.
  • 2 State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. [email protected].
  • 3 State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, and Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin, China. [email protected].
  • # Contributed equally.
Abstract

Atherosclerosis (AS) is a leading cause of cardiovascular and cerebrovascular disease and is driven by lipid accumulation and chronic inflammation within arterial plaques. Foam cells play a central role in plaque growth and destabilization, yet their precise diagnosis and targeted regulation remain challenging. Here we present a hierarchical nanoagent that integrates multimodal imaging with selective foam cell intervention for improved AS management. The molecular probe enables near-infrared II fluorescence, photoacoustic, and magnetic resonance imaging, providing complementary information on plaque location, depth, and morphology. To achieve targeted therapy, the probe is co-encapsulated with atorvastatin using responsive nanocarriers camouflaged with macrophage membranes and equipped with a foam cell-targeting peptide. This hierarchical strategy enables precise targeting to inflamed plaques and foam cells, where controlled drug release promotes lipid efflux, reduces inflammatory signaling, and enhances plaque stabilization in female AS mouse models. This integrated imaging-guided therapeutic platform holds great promise for precise diagnosis and treatment of Cardiovascular Disease.

Figures
Products
Inhibitors & Agonists
Other Products